Cas no 231277-92-2 (Lapatinib)

Lapatinib is an oral tyrosine kinase inhibitor that targets HER2 and EGFR receptors, offering a dual-action mechanism to inhibit tumor growth in breast cancer cells. Its advantages include improved efficacy in HER2-positive tumors and synergistic effects with hormonal therapies, enhancing treatment outcomes while minimizing side effects.

Lapatinib structure

Product Name:Lapatinib

CAS No:231277-92-2

MF:C₂₉H₂₆ClFN₄O₄S

MW:581.057548046112

MDL:MFCD09264194

CID:67125

PubChem ID:329796232

Update Time:2025-09-04

Lapatinib Chemical and Physical Properties

Names and Identifiers

- Lapatinib Base N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-Quinazolinamine
- GW2016 LAPATINIB
- GW-572016
- TYKERB
- lapatinib
- n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl]quinazolin-4-amine
- 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-
- Lapatinib(TINIBS)
- GW572016
- Lapatinib ( GSK572016,GW2016,GW-572016)
- Lapatinib base
- 4-{[3-chloro-4-(3-fluoro-benzyloxy)-phenyl]amino}-6-(5-{[(2-methanesulphonyl-ethyl)amino]methyl}-furan-2-yl)quinazoline
- 4-{[3-chloro-4-(3-fluoro-benzyloxy)-phenyl]amino}-6-(5-{[(2-methansulfonyl-ethyl)amino]methyl}-furan-2-yl)quinazoline
- N-{3-Chloro-4-[(3-fluorobenzyl) oxy]phenyl}-6-[5-({[2-(methanesulphonyl) ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
- N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethy
- GW 572016
- Lapatinib tosilate hydrate
- Lapatinib [INN]
- Tyverb
- Lapatinib (INN)
- Lapatinib free base
- GSK 572016
- GSK572016
- FMM
- N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE
- 0VUA21238F
- NSC745750
- C29H26ClFN4O4S
- DSSTox_RID_81812
- DSSTox_CID_26675
- DSSTox_GSID_46675
- N-{3-chloro-4-[(3-fluorophenyl)me
- GW2016
- N-{3-chloro-4-[(3-fluorophenyl)methoxy]phenyl}-6-(5-{[(2-methanesulfonylethyl)amino]methyl}furan-2-yl)quinazolin-4-amine
- NCGC00167507-02
- DTXSID7046675
- 231277-92-2
- Tykerb (TN) (Glaxo Smith Kline)
- Tox21_112505
- MFCD09264194
- NSC800780
- AB01273965-01
- SR-05000001472-1
- CCG-270133
- AB01273965-03
- GW 282974X
- N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
- BCP9000838
- nchembio866-comp20
- BCP9000837
- HMS2089H10
- HSDB 8209
- AB01273965-02
- FT-0659650
- HY-50898
- UNII-0VUA21238F
- D08108
- CHEBI:49603
- 1092929-10-6
- Lapatinib Ditosylate
- Tox21_112505_1
- N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine
- 4-Quinazolinamine, N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-
- NCGC00167507-09
- GW-2016
- Lapatinib base- Bio-X
- HMS3244N06
- EX-A402
- N-[3-chloro-4-(3-fluorobenzyloxy)phenyl]-6-[5-({[2-(methanesulfonyl)ethyl]amino}methyl)furan-2-yl]quinazolin-4-amine
- AC-1314
- N-{3-chloro-4-[(3-fluoro-benzyl)oxy]phenyl}-6-[5-({2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
- NSC-800780
- BRD-K19687926-001-01-7
- SCHEMBL8100
- DB01259
- Lapatinib, Free base
- AS-14065
- EN300-117254
- N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
- DTXCID5026675
- SW199101-5
- Lapatinib [INN:BAN]
- N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine
- N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl] quinazolin-4-amine
- BC164610
- NS00003012
- N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)furan-2-yl]quinazolin-4-amine
- Q420323
- N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
- A25184
- Lapatinib (GW572016)
- N-{3-Chloro-4[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methane sulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
- GW-572016X
- 231277-92-2 (free base)
- NCGC00167507-03
- N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine
- NSC-745750
- LAPATINIB [MI]
- GTPL5692
- LAPATINIB [WHO-DD]
- Kinome_3685
- AM20090641
- N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)furan-2-yl)quinazolin-4-amine
- BCPP000189
- CHEMBL554
- NCGC00167507-01
- Lapatinib (free base)
- NCGC00167507-04
- n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-quinazolinamine
- GSK-572016
- BCP01874
- AB01273965_04
- GW-2016;N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)furan-2-yl)quinazolin-4-amine;4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline
- BDBM5445
- HMS3744K11
- LAPATINIB [VANDF]
- L0360
- BCPP000188
- N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((2-(methylsulfonyl)ethylamino)methyl)furan-2-yl)quinazolin-4-amine
- cid_208908
- HMS3244N10
- N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methane sulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
- Kinome_3684
- Q-101353
- SB16918
- 1210608-87-9
- 913989-15-8
- AB01273965_05
- HMS3244N14
- CAS-231277-92-2
- LAPATINIB [EMA EPAR]
- 1xkk
- BCFGMOOMADDAQU-UHFFFAOYSA-N
- BRD-K19687926-379-02-5
- AKOS005145766
- BRD-K19687926-001-10-8
- BRD-K19687926-001-04-1
- SDCCGSBI-0634417.P003
- Lapatinib ditosylate?
- BRD-K19687926-379-07-4
- Lapatinib?
- Lapatinib
- MDL： MFCD09264194
- Inchi： 1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)
- InChI Key： BCFGMOOMADDAQU-UHFFFAOYSA-N
- SMILES： ClC1=C(C=CC(=C1)NC1=C2C(C=CC(=C2)C2=CC=C(CNCCS(C)(=O)=O)O2)=NC=N1)OCC1C=CC=C(C=1)F

Computed Properties

Exact Mass: 580.13500
Monoisotopic Mass: 580.134732
Isotope Atom Count: 0
Hydrogen Bond Donor Count: 2
Hydrogen Bond Acceptor Count: 9
Heavy Atom Count: 40
Rotatable Bond Count: 11
Complexity: 898
Covalently-Bonded Unit Count: 1
Defined Atom Stereocenter Count: 0
Undefined Atom Stereocenter Count : 0
Defined Bond Stereocenter Count: 0
Undefined Bond Stereocenter Count: 0
Surface Charge: 0
Tautomer Count: 3
XLogP3: 5.1
Topological Polar Surface Area: 115

Experimental Properties

Color/Form: Powder
Density: 1.381
Melting Point: 136-140°C
Boiling Point: 750.7°C at 760 mmHg
Flash Point: 407.8 °C
Refractive Index: 1.645
PSA: 114.73000
LogP: 7.68380

Lapatinib Security Information

Signal Word：Warning
Hazard Statement： H315; H319; H335
Warning Statement： P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501
Hazardous Material transportation number：UN 3275 6.1/PG 2
WGK Germany：3
Safety Instruction： S26; S36/37/39; S45
Hazardous Material Identification：
Storage Condition：Powder -20°C 3 years ? 4°C 2 years In solvent -80°C 6 months ? -20°C 1 month
Risk Phrases：R10; R23/24/25; R34; R36/37/38
Packing Group：II
Safety Term：6.1
Packing Group：II
Hazard Level：6.1

Lapatinib Customs Data

HS CODE：2934999090
Customs Data：

China Customs Code:
2934999090

Overview:

2934999090. Other heterocyclic compounds. VAT:17.0%. Tax refund rate:13.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:20.0%

Declaration elements:

Product Name, component content, use to

Summary:

2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Lapatinib Pricemore >>

Related Categories	No.	Product Name	Cas No.	Purity	Specification	Price	update time
YUN NAN XI LI SHENG WU JI SHU GU FEN Co., Ltd.	BBP80350-5mg	Lapatinib	231277-92-2	98.0%	5mg	￥100	2021-05-07
S e l l e c k ZHONG GUO	S2111-10mM (1mL in DMSO)	Lapatinib	231277-92-2	99.95%	10mM (1mL in DMSO)	￥794.43	2023-09-15
S e l l e c k ZHONG GUO	S2111-25mg	Lapatinib	231277-92-2	99.95%	25mg	￥647.01	2023-09-15
S e l l e c k ZHONG GUO	S2111-100mg	Lapatinib	231277-92-2	99.95%	100mg	￥1392.3	2023-09-15
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.	L126696-25mg	Lapatinib	231277-92-2	≥99%	25mg	￥29.90	2023-09-02
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.	L126696-250mg	Lapatinib	231277-92-2	≥99%	250mg	￥114.90	2023-09-02
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.	L126696-500mg	Lapatinib	231277-92-2	≥99%	500mg	￥216.90	2023-09-02
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.	L126696-100mg	Lapatinib	231277-92-2	≥99%	100mg	￥56.90	2023-09-02
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.	L126696-5g	Lapatinib	231277-92-2	≥99%	5g	￥1470.90	2023-09-02
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.	L126696-1g	Lapatinib	231277-92-2	≥99%	1g	￥395.90	2023-09-02

Lapatinib Production Method

Lapatinib Suppliers

Tiancheng Chemical (Jiangsu) Co., Ltd

Gold Member

Audited Supplier

(CAS:231277-92-2)拉帕替尼

Order Number:LE26638612

Stock Status:in Stock

Quantity:25KG,200KG,1000KG

Purity:99%

Pricing Information Last Updated:Friday, 20 June 2025 12:56

Price ($):discuss personally

Email:[email protected]

Suzhou Senfeida Chemical Co., Ltd

Gold Member

Audited Supplier

(CAS:231277-92-2)Lapatinib

Order Number:sfd19744

Stock Status:in Stock

Quantity:200kg

Purity:99.9%

Pricing Information Last Updated:Friday, 19 July 2024 14:38

Price ($):discuss personally

Email:[email protected]

Product Official Link

Lapatinib Spectrogram

1H NMR

300 MHz

DMSO

MS-MS

13C NMR

Lapatinib Related Literature

1. Binding-induced, turn-on fluorescence of the EGFR/ERBB kinase inhibitor, lapatinib

James N. Wilson,Wenjun Liu,Adrienne S. Brown,Ralf Landgraf Org. Biomol. Chem. 2015 13 5006
2. Dynamic transcription factor activity and networks during ErbB2 breast oncogenesis and targeted therapy

M. S. Weiss,B. Pe?alver Bernabé,S. Shin,S. Asztalos,S. J. Dubbury,M. D. Mui,A. D. Bellis,D. Bluver,D. A. Tonetti,J. Saez-Rodriguez,L. J. Broadbelt,J. S. Jeruss,L. D. Shea Integr. Biol. 2014 6 1170
3. Synthesis, characterization and biological evaluation of formononetin derivatives as novel EGFR inhibitors via inhibiting growth, migration and inducing apoptosis in breast cancer cell line

Hong-Yan Lin,Wen-Xue Sun,Chao-Sai Zheng,Hong-Wei Han,Xue Wang,Ya-Han Zhang,Han-Yue Qiu,Cheng-Yi Tang,Jin-Liang Qi,Gui-Hua Lu,Rong-Wu Yang,Xiao-Ming Wang,Yong-Hua Yang RSC Adv. 2017 7 48404
4. HER2 and Src co-regulate proliferation, migration and transformation by downstream signaling pathways in arsenite-treated human uroepithelial cells

Qing Zhou,Peiyu Jin,Jieyu Liu,Fei Wang,Shuhua Xi Metallomics 2018 10 1141
5. An environmentally responsible synthesis of the antitumor agent lapatinib (Tykerb)

Julie Yu,Karthik S. Iyer,Bruce H. Lipshutz Green Chem. 2022 24 3640

Related Categories

231277-92-2 (Lapatinib) Related Products

Recommended suppliers